Abstract

SO.11.03

Comparison of intravitreal Bevacizumab (Avastin) versus Triamcinolone in diabetic macular edema

AlSaeidi R., Kook D., Wolf A., Haritoglou C., Kampik A., Neubauer A.
University Eye Hospital, Munich

Objective: Besides Triamcinolone various anti-VEGF substances are available for the intravitreal therapy of diabetic macular edema, of which especially Bevacizumab (Avastin) has been applied recently.
Methods: To a consecutives series of 32 patients, who had been treated by a single 4mg intravitreal Triamcinolone injection, 32 patients were matched („Matched Pairs“), who had received three injections of 1,25 mg Bevacizumab over 3 months. Both groups did not differ regarding preoperative visual acuity (VA) and central retina thickness on OCT. Outcome variables were the VA and OCT thickness change 3 months after therapy.
Results: Before therapy VA was 0.72±0.39 logMAR and retina thickness on OCT 548±185 micrometers. After Triamcinolone the VA increased on average by -0,07 logMAR (p=0.048) versus -0.02 logMAR (n.s.) after repeated Bevacizumab injections (difference n.s.). Both therapies reduced retinal thickness significantly (p=0.001). The effect was significantly larger (p=0.04) for Triamcinolone (-176 microns) than for Bevacizumab (-108 microns).
Conclusions: Given the limitations of the study design the effect of a single Triamcinolone injection appears to be stronger than a 3 times repeated intravitreal administration of Bevacizmab for diabetic macular edema.

Copyright: Porstmann Kongresse GmbH. All rights reserved. Impressum, Disclaimer.